Research and Markets: Non-Small Cell Lung Cancer Thought Leader Panel #36 2013-09
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ndwx94/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer Thought Leader Panel #36 2013-09" report to their offering.
“Non-Small Cell Lung Cancer Thought Leader Panel #36 2013-09”
Thought Leader Panel #36, published September 2013, shares key insights gleaned from our Panel of experts in non-small cell lung cancer during interviews conducted since ASCO 2013. This report focuses on adenocarcinomas and squamous cell carcinomas of the lung.
There is little discussion of other lung cancers with partial or IHC adenocarcinoma differentiation (e.g. large cell carcinomas, small cell carcinomas or large cell endocrine carcinomas, brief comments on adenosquamous carcinomas in the section on the SQUIRE trial with necitumumab). The report is generally organized by target mechanism.
More than a decade since EGFR was identified as a substantial driver for adenocarcinomas, and five years since the importance of ALK fusions was shown, the targets for treatment of this histology has matured. We share our Panel's opinions on next generation EGFR and ALK inhibitors, and newer targets: ROS, RET, HER2 and others.
In contrast, squamous cell carcinomas of the lung lack an approved targeted therapy. While less mature, it looks like this will change shortly, as FGF1 inhibitors make their way through development.
The major story in the solid tumor world this year has been the explosive development in the area of checkpoint modulation. There is speculation that PD1 and other checkpoint approaches will be most beneficial in the squamous NSCLCs. The Panel reviews the safety and efficacy data presented on the PD-1 and PD-L1 inhibitors.
Finally, the Panel sheds light on PI3K in brain metastases, CDK4/6, HSP90 and other topics that will impact the changing landscape of NSCLC in the next few years.
Mechanisms / Drugs discussed in this report:
- ALK, Xalkori, crizotinib, Pfizer, LDK378, Novartis, AP26113, Ariad, RO5424802, CH5424802,
- AF802, Chugai, Roche, ASP3026, Astellas,
- AXL, BGB324, BerGenBio,
- CDK4/6, LY2835219, Lilly,
- CTLA4, Yervoy, ipilimumab, BMS,
- DDR2, Sprycel, dasatinib, BMS,
- EGFR, Tarceva, erlotinib, Genentech, Astellas, necitumumab Lilly, CO-1686, Clovis, AP26113,
- Ariad, AZD9291, AstraZeneca,
- EGFR/HER2, Gilotrif, afatinib, Boehringer-Ingelheim, dacomitinib, Pfizer,
- FGF, BGJ398, Novartis, JNJ-42756493, Astex, Janssen, AZD-4547, AstraZeneca, Iclusig, ponatinib,
- Ariad, LY-2874455, Lilly, SSR128129E, Sanofi-Aventis,
- Folate, Alimta, pemetrexed, Lilly, vintafolide, Merck, Endocyte,
- HSP90, ganetespib, Synta, AUY922, Novartis, AT13387, Astex, retaspimycin, IPI-504, Infinity,
- MEK, selumetinib, AstraZeneca, Array, MEK-162, Novartis, Array,
- MET, onartuzumab, MetMAb, Genentech,
- MUC1, Stimuvax, L-BLP25, Oncothyreon, Merck Serono,
- PD-1, PD-L1, MPDL3280A, Genentech, lambrolizumab, MK-3475, Merck, nivolumab, BMS, Ono,
- ANB011, AnaptysBio,
- PI3K, brain metastases,
- PS, bavituximab, Peregrine,
- Reovirus, Reolysin, pelareorep, Oncolytics,
- RET Fusion, cabozantinib, Cometriq, Exelixis, Iclusig, ponatinib, Ariad,
- ROS1, Xalkori, crizotinib, Pfizer,
- Vaccine, MAGE-A3, GlaxoSmithKline, Agenus,
- VEGF, Avastin, bevacizumab, Genentech, Vargatef, nintedanib, Boehringer-Ingelheim
For more information visit http://www.researchandmarkets.com/research/ndwx94/nonsmall_cell
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.